Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice

  • Huizi Tan
  • Jianxin Zhao
  • Hao Zhang
  • Qixiao ZhaiEmail author
  • Wei Chen
Applied microbial and cell physiology


Lipopolysaccharide (LPS) can promote the expression of pro-inflammatory cytokines, damage the tight junction of epithelial walls, and thereby lead to chronic low-grade intestinal inflammatory disorders. Evidences of many beneficial functions from Bacteroides strains suggest their intervention capabilities in LPS-induced inflammation. In the present study, both healthy and LPS-treated mice were consistently treated with Bacteroides strains for 5 days. The intestinal microbiota alteration, epithelial permeability, cytokine expression, and autoimmune and innate immune responses were analyzed. B. fragilis HCK-B3 and B. ovatus ELH-B2 from our laboratory collection were demonstrated to assist intestinal equilibrium by maintaining the diversity of gut microbiota and relieve LPS-induced inflammation by either modulating cytokine production or restoring the Treg/Th-17 balance. Our research indicated that the Bacteroides strains with capabilities of alleviating inflammation have the potential as therapeutics to prevent intestinal inflammatory disorders and provided scientific supports for discovering next-generation probiotics.


Bacteroides Inflammation Lipopolysaccharide Next-generation probiotics Regulatory T cells 



This work was supported by the Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province. We acknowledge Dr. Pinghu Zhang from China Pharmaceutical University for raising the animals.


This work was funded by the National Natural Science Foundation of China (No. 31601452), the National Natural Science Foundation of China Key Program (No. 31530056), the Natural Science Foundation of Jiangsu Province (BK20160175), and the National First-Class Discipline Program of Food Science and Technology (JUFSTR20180102).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving animals were approved by the Animal Ethics Committee of China Pharmaceutical University (CPU20170546), and the protocols for the care and use of the mice were based on European Community guidelines (Directive 2010/63/EU).


  1. Bai AP, Lu NH, Guo Y, Liu ZJ, Chen J, Peng ZK (2009) All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol 86(4):959–969. CrossRefGoogle Scholar
  2. Bettelli E, Oukka M, Kuchroo VK (2007) TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8(4):345–350. CrossRefGoogle Scholar
  3. Cani PD, de Vos WM (2017) Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 8:8. CrossRefGoogle Scholar
  4. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8):1091–1103. CrossRefGoogle Scholar
  5. Cano PG, Santacruz A, Moya A, Sanz Y (2012) Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high fat diet induced obesity. PLoS One 7(7):16. Google Scholar
  6. Cavalcanti Neto MP, Aquino JS, Romao da Silva LF, de Oliveira Silva R, Guimaraes KSL, de Oliveira Y, de Souza EL, Magnani M, Vidal H, de Brito Alves JL (2018) Gut microbiota and probiotics intervention: a potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease? Pharmacol Res 130:152–163. CrossRefGoogle Scholar
  7. Chatzidaki-Livanis M, Coyne MJ, Comstock LE (2014) An antimicrobial protein of the gut symbiont Bacteroides fragilis with a MACPF domain of host immune proteins. Mol Microbiol 94(6):1361–1374. CrossRefGoogle Scholar
  8. Chatzidaki-Livanis M, Geva-Zatorsky N, Comstock LE (2016) Bacteroides fragilis type VI secretion systems use novel effector and immunity proteins to antagonize human gut Bacteroidales species. Proc Natl Acad Sci U S A 113(13):3627–3632. CrossRefGoogle Scholar
  9. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HMB, Coakley M, Lakshminarayanan B, O’Sullivan O, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, O’Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488(7410):178–184. CrossRefGoogle Scholar
  10. Cohen-Poradosu R, McLoughlin RM, Lee JC, Kasper DL (2011) Bacteroides fragilis-stimulated interleukin-10 contains expanding disease. J Infect Dis 204(3):363–371. CrossRefGoogle Scholar
  11. Deng HM, Li ZC, Tan YF, Guo ZB, Liu YY, Wang Y, Yuan Y, Yang RF, Bi YJ, Bai Y, Zhi FC (2016) A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages. Sci Rep 6:11. CrossRefGoogle Scholar
  12. Gerard P, Lepercq P, Leclerc M, Gavini F, Raibaud P, Juste C (2007) Bacteroides sp strain D8, the first cholesterol-reducing bacterium isolated from human feces. Appl Environ Microbiol 73(18):5742–5749. CrossRefGoogle Scholar
  13. Guo SH, Al-Sadi R, Said HM, Ma TY (2013) Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 182(2):375–387. CrossRefGoogle Scholar
  14. Guo SH, Nighot M, Al-Sadi R, Alhmoud T, Nighot P, Ma TY (2015) Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol 195(10):4999–5010. CrossRefGoogle Scholar
  15. Hamady ZZR, Scott N, Farrar MD, Lodge JPA, Holland KT, Whitehead T, Carding SR (2010) Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59(4):461–469. CrossRefGoogle Scholar
  16. Hamady ZZR, Scott N, Farrar MD, Wadhwa M, Dilger P, Whitehead TR, Thorpe R, Holland KT, Lodge JPA, Carding SR (2011) Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-beta1 under the control of dietary xylan. Inflamm Bowel Dis 17(9):1925–1935. CrossRefGoogle Scholar
  17. Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830–1835. CrossRefGoogle Scholar
  18. Laetitia R, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S (2013) Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 23(4):518–526CrossRefGoogle Scholar
  19. Ling X, Peng LL, Du WX, Hong W (2016) Protective effects of Bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. PLoS One 11(8):17. CrossRefGoogle Scholar
  20. Liu Y, Wu H, Nie YC, Chen JL, Su WW, Li PB (2011) Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-kappa B pathway. Int Immunopharmacol 11(10):1606–1612. CrossRefGoogle Scholar
  21. Luongo D, Coppola A, Treppiccione L, Bergamo P, Sorrentino A, Ferrocino I, Turroni S, Neviani E, Di Cagno R, Cocolin L, Rossi M (2016) Modulation of the cytokine profile in Caco-2 cells by faecal lactobacilli and bifidobacteria from individuals with distinct dietary habits. Cytokine 90:80–87. CrossRefGoogle Scholar
  22. Maes M, Kubera M, Leunis JC (2008) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett 29(1):117–124Google Scholar
  23. Mao BY, Li DY, Zhao JX, Liu XM, Gu ZN, Chen YQ, Zhang H, Chen W (2015) Metagenomic insights into the effects of fructo-oligosaccharides (FOS) on the composition of fecal microbiota in mice. J Agric Food Chem 63(3):856–863. CrossRefGoogle Scholar
  24. Mays LE, Wang LL, Lin JP, Bell P, Crawford A, Wherry EJ, Wilson JM (2014) AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 22(1):28–41. CrossRefGoogle Scholar
  25. Mazmanian SK, Kasper DL (2006) The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 6(11):849–858. CrossRefGoogle Scholar
  26. Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453(7195):620–625. CrossRefGoogle Scholar
  27. O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O’Mahony L (2008) Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappa B activation. PLoS Pathog 4(8):10. Google Scholar
  28. O’Toole PW, Marchesi JR, Hill C (2017) Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2(5):6. Google Scholar
  29. Olli K, Saarinen MT, Forssten SD, Madetoja M, Herzig K-H, Tiihonen K (2016) Independent and combined effects of lactitol, polydextrose, and Bacteroides thetaiotaomicron on postprandial metabolism and body weight in rats fed a high-fat diet. Front Nutr 3:15. CrossRefGoogle Scholar
  30. Osaka T, Moriyama E, Arai S, Date Y, Yagi J, Kikuchi J, Tsuneda S (2017) Meta-analysis of fecal microbiota and metabolites in experimental colitic mice during the inflammatory and healing phases. Nutrients 9(12).
  31. Rakoff-Nahoum S, Coyne MJ, Comstock LE (2014) An ecological network of polysaccharide utilization among human intestinal symbionts. Curr Biol 24(1):40–49. CrossRefGoogle Scholar
  32. Rakoff-Nahoum S, Foster KR, Comstock LE (2016) The evolution of cooperation within the gut microbiota. Nature 533(7602):255–259. CrossRefGoogle Scholar
  33. Roelofs KG, Coyne MJ, Gentyala RR, Chatzidaki-Livanis M, Comstock LE (2016) Bacteroidales secreted antimicrobial proteins target surface molecules necessary for gut colonization and mediate competition in vivo. mBio 7(4).
  34. Rossi O, van Berkel LA, Chain F, Khan MT, Taverne N, Sokol H, Duncan SH, Flint HJ, Harmsen HJM, Langella P, Samsom JN, Wells JM (2016) Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep 6:12. CrossRefGoogle Scholar
  35. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK (2011) The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332(6032):974–977. CrossRefGoogle Scholar
  36. Sjodin KS, Vidman L, Ryden P, West CE (2016) Emerging evidence of the role of gut microbiota in the development of allergic diseases. Curr Opin Allergy Clin Immunol 16(4):390–395. CrossRefGoogle Scholar
  37. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105(43):16731–16736. CrossRefGoogle Scholar
  38. Ulsemer P, Henderson G, Toutounian K, Loffler A, Schmidt J, Karsten U, Blaut M, Goletz S (2013) Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6. Cancer Immunol Immunother 62(5):875–887. CrossRefGoogle Scholar
  39. Ulsemer P, Toutounian K, Kressel G, Goletz C, Schmidt J, Karsten U, Hahn A, Goletz S (2016) Impact of oral consumption of heat-treated Bacteroides xylanisolvens DSM 23964 on the level of natural TF alpha-specific antibodies in human adults. Benef Mirbobes 7(4):485–500. CrossRefGoogle Scholar
  40. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hamalainen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lahdesmaki H, Huttenhower C, Gevers D, Cullen TW, Knip M, Xavier RJ, Grp DS (2016) Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165(4):842–853. CrossRefGoogle Scholar
  41. Wei H, Dong L, Wang TT, Zhang MH, Hua WY, Zhang CH, Pang XY, Chen MJ, Su MM, Qiu YP, Zhou MM, Yang SL, Chen Z, Rantalainen M, Nicholson JK, Jia W, Wu DZ, Zhao LP (2010) Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes induced by carcinogen exposure. FEMS Microbiol Ecol 73(3):577–586. Google Scholar
  42. Wexler AG, Goodman AL (2017) An insider’s perspective: Bacteroides as a window into the microbiome. Nat Microbiol 2(5):11. CrossRefGoogle Scholar
  43. Yanagibashi T, Hosono A, Oyama A, Tsuda M, Suzuki A, Hachimura S, Takahashi Y, Momose Y, Itoh K, Hirayama K, Takahashi K, Kaminogawa S (2013) IgA production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes IgA production in the large intestine by inducing germinal center formation and increasing the number of IgA(+) B cells. Immunobiology 218(4):645–651. CrossRefGoogle Scholar
  44. Yim S, Gwon SY, Hwang S, Kim NH, Jung BD, Rhee KJ (2013) Enterotoxigenic Bacteroides fragilis causes lethal colitis in Mongolian gerbils. Anaerobe 21:64–66. CrossRefGoogle Scholar
  45. Yin L, Kufe T, Avigan D, Kufe D (2014) Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood 123(19):2997–3006. CrossRefGoogle Scholar
  46. Zhang PH, Zhang LY, Jiang ZZ, Xiong YT, Chen HK, Tao YQ, Hu MZ, Li Z (2011) Evaluation of mitochondrial toxicity in Marmota himalayana treated with Metacavir, a novel 2′,3′-dideoxyguanosine prodrug for treatment of hepatitis B virus. Antimicrob Agents Chemother 55(5):1930–1936. CrossRefGoogle Scholar
  47. Zhang Q, Ai C, Wang G, Liu X, Tian F, Zhao J, Zhang H, Chen YQ, Chen W (2015) Oral application of lactic acid bacteria following treatment with antibiotics inhibits allergic airway inflammation. J Appl Microbiol 119(3):809–817. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.State Key Laboratory of Food Science and TechnologyJiangnan UniversityWuxiPeople’s Republic of China
  2. 2.School of Food Science and TechnologyJiangnan UniversityWuxiPeople’s Republic of China
  3. 3.National Engineering Research Center for Functional FoodJiangnan UniversityWuxiPeople’s Republic of China
  4. 4.International Joint Research Laboratory for Probiotics at Jiangnan UniversityWuxiChina
  5. 5.Beijing Innovation Center of Food Nutrition and Human HealthBeijing Technology and Business University (BTBU)BeijingPeople’s Republic of China

Personalised recommendations